Opalescence in Monoclonal Antibody Solutions and Its Correlation with Intermolecular Interactions in Dilute and Concentrated Solutions

Journal of Pharmaceutical Sciences

Volumn 104, Issue 4, 2015, Pages 1263-1274

  Raut, Ashlesha S ^a   Kalonia, Devendra S ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

light scattering; liquid liquid phase separation; monoclonal antibody; opalescence; physical characterization; Protein; protein formulation; protein protein interactions; rheology; stability

Indexed keywords

MONOCLONAL ANTIBODY; SOLUTION AND SOLUBILITY;

AREA UNDER THE CURVE; ARTICLE; CHEMICAL PARAMETERS; DRUG FORMULATION; LIGHT SCATTERING; LIQUID LIQUID EXTRACTION; MOLECULE; OPALESCENCE; OSMOMETRY; PHASE SEPARATION; PROTEIN PROTEIN INTERACTION; TEMPERATURE DEPENDENCE; ZETA POTENTIAL; CHEMICAL MODEL; CHEMISTRY; DRUG STABILITY; FLOW KINETICS; IRIDESCENCE; LIGHT; MEDICINAL CHEMISTRY; OSMOLARITY; PHARMACEUTICS; PROCEDURES; PROTEIN DENATURATION; PROTEIN STABILITY; RADIATION SCATTERING; SOLUBILITY; SOLUTION AND SOLUBILITY; TEMPERATURE;

ANTIBODIES, MONOCLONAL; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; IRIDESCENCE; LIGHT; MODELS, CHEMICAL; OSMOLAR CONCENTRATION; PHARMACEUTICAL SOLUTIONS; PROTEIN DENATURATION; PROTEIN STABILITY; RHEOLOGY; SCATTERING, RADIATION; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 84924806244     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24326     Document Type: Article

References (51)

1. An Z. 2010. Monoclonal antibodies - A proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1(4):319-330.
2. Elbakri A, Nelson PN, Abu Odeh RO. 2010. The state of antibody therapy. Hum Immunol 71(12):1243-1250.
3. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6):1390-1402.
4. Harris RJ, Shire SJ, Winter C. 2004. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Dev Res 61:137-154.
5. Daugherty AL, Mrsny RJ. 2006. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 58(5-6):686-706.
6. Saluja A, Kalonia DS. 2008. Nature and consequences of protein-protein interactions in high protein concentration solutions. Int J Pharm 358(1-2):1-15.
7. Hall D, Minton AP. 2003. Macromolecular crowding: Qualitative and semiquantitative successes, quantitative challenges. Biochim Biophys Acta 1649(2):127-139.
8. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96(1):1-26.
9. Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289(1-2):1-30.
10. Sukumar M, Doyle BL, Combs JL, Pekar AH. 2004. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm Res 21(7):1087-1093.
11. Salinas BA, Sathish HA, Bishop SM, Harn N, Carpenter JF, Randolph TW. 2010. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci 99(1):82-93.
12. Woods JM, Nesta D. 2010. Formulation effects on opalescence of a high-concentration MAb. BioProcess Int 8(9):48-59.
13. Nishi H, Miyajima M, Nakagami H, Noda M, Uchiyama S, Fukui K. 2010. Phase separation of an IgG1 antibody solution under a low ionic strength condition. Pharm Res 27(7):1348-1360.
14. Mason BD, Zhang L, Remmele RL Jr., Zhang J. 2011. Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid-liquid phase separation. J Pharm Sci 100(11):4587-4596.
15. Wang N, Hu B, Ionescu R, Mach H, Sweeney J, Hamm C, Kirchmeier MJ, Meyer BK. 2009. Opalescence of an IgG1 monoclonal antibody formulation is mediated by ionic strength and excipients. Bio-Pharm Int 22(4):36-47.
16. Nishi H, Miyajima M, Wakiyama N, Kubota K, Hasegawa J, Uchiyama S, Fukui K. 2011. Fc domain mediated self-association of an IgG1 monoclonal antibody under a low ionic strength condition. J Biosci Bioeng 112(4):326-332.
17. Vekilov PG. 2012. Phase diagrams and kinetics of phase transitions in protein solutions. J Phys Condens Matter 24(19):193101.
18. Siezen RJ, Fisch MR, Slingsby C, Benedek GB. 1985. Opacification of gamma-crystallin solutions from calf lens in relation to cold cataract formation. Proc Natl Acad Sci USA 82(6):1701-1705.
19. Pande A, Pande J, Asherie N, Lomakin A, Ogun O, King J, Benedek GB. 2001. Crystal cataracts: Human genetic cataract caused by protein crystallization. Proc Natl Acad Sci USA 98(11):6116-6120.
20. Eaton WA, Hofrichter J. 1990. Sickle cell hemoglobin polymerization. Adv Protein Chem 40:63-279.
21. Koo EH, Lansbury PT Jr., Kelly JW. 1999. Amyloid diseases: Abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA 96(18):9989-9990.
22. Yagi H, Takahashi N, Yamaguchi Y, Kato K. 2004. Temperature-dependent isologous Fab-Fab interaction that mediates cryocrystallization of a monoclonal immunoglobulin G. Mol Immunol 41(12):1211-1215.
23. Saluja A, Kalonia DS. 2005. Application of ultrasonic shear rheometer to characterize rheological properties of high protein concentration solutions at microliter volume. J Pharm Sci 94(6):1161-1168.
24. Saluja A, Badkar AV, Zeng DL, Nema S, Kalonia DS. 2006. Application of high-frequency rheology measurements for analyzing protein-protein interactions in high protein concentration solutions using a model monoclonal antibody (IgG2). J Pharm Sci 95(9):1967-1983.
25. Saluja A, Badkar AV, Zeng DL, Nema S, Kalonia DS. 2007. Ultrasonic storage modulus as a novel parameter for analyzing protein-protein interactions in high protein concentration solutions: Correlation with static and dynamic light scattering measurements. Biophys J 92(1):234-244.
26. Yadav S, Liu J, Shire SJ, Kalonia DS. 2010. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci 99(3):1152-1168.
27. Yadav S, Shire SJ, Kalonia DS. 2010. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci 99(12):4812-4829.
28. Yadav S, Shire SJ, Kalonia DS. 2012. Viscosity behavior of high-concentration monoclonal antibody solutions: Correlation with interaction parameter and electroviscous effects. J Pharm Sci 101(3):998-1011.
29. Chari R, Jerath K, Badkar AV, Kalonia DS. 2009. Long- and short-range electrostatic interactions affect the rheology of highly concentrated antibody solutions. Pharm Res 26(12):2607-2618.
30. Hunter RJ. 1981. The calculation of zeta potential. In Zeta potential in colloid science: Principles and applications; Ottewill RH, Rowell RL, Eds. New York: Academic Press, pp 59-124.
31. Chun MS, Lee I. 2008. Rigorous estimation of effect protein charge from experimental electrophoretic mobilities for proteomics analysis using microchip electrophoresis. Colloids Surf A 318:191-198.
32. Berne BJ, Pecora R. 2000. Dynamic light scattering: With applications to chemistry, biology, and physics. Courier Dover Publications, New York, NY.
33. Yadav S, Scherer TM, Shire SJ, Kalonia DS. 2011. Use of dynamic light scattering to determine second virial coefficient in a semidilute concentration regime. Anal Biochem 411(2):292-296.
34. Hubter RJ. 2001. Foundation of colloidal science, vol 1. Oxford University Press, New York, NY.
35. Lutanie E, Voegel JC, Schaaf P, Freund M, Cazenave JP, Schmitt A. 1992. Competitive adsorption of human immunoglobulin G and albumin: Consequences for structure and reactivity of the adsorbed layer. Proc Natl Acad Sci USA 89(20):9890-9894.
36. David C, Millot MC, Renard E, Sebille B. 2002. Coupling of antibodies to b-cyclodextrin-coated gold surfaces via an intermediate adamantyl-modified carboxymethylated dextran layer. J Inclusion Phenom Macro Chem 44:369-372.
37. Saluja A, Kalonia DS. 2004. Measurement of fluid viscosity at microliter volumes using quartz impedance analysis. AAPS PharmSciTech 5(3):e47.
38. Stanley HE. 1987. Introduction to phase transitions and critical phenomena. Oxford University Press, New York, NY.
39. Beysens D, Straub J, Turner DJ. 1987. Phase transition and near critical phenomena. Berlin, Germany: Springer.
40. Gopal ESR. 2000. Critical opalescence. Resonance 5(4):37-45.
41. van Dijk MA, Wakker A. 1998. Concepts in polymer thermodynamics. CRC Press, Lancaser, PA.
42. Atkins P, De Paula J. 2014. Atkins' physical chemistry. Oxford University Press, Oxford, UK.
43. Hiemenz PC, Rajagopalan R. 1997. Principles of colloid and surface chemistry. 3rd ed. New York: Marcel Dekker, Inc, New York, NY.
44. Wang Y, Lomakin A, Latypov RF, Benedek GB. 2011. Phase separation in solutions of monoclonal antibodies and the effect of human serum albumin. Proc Natl Acad Sci USA 108(40):16606-16611.
45. Zhou HX, Rivas G, Minton AP. 2008. Macromolecular crowding and confinement: Biochemical, biophysical, and potential physiological consequences. Annu Rev Biophys 37:375-397.
46. Laue T. 2012. Proximity energies: A framework for understanding concentrated solutions. J Mol Recognit 25(3):165-173.
47. Israelachvili JN. 2011. Intermolecular and surface forces. 3rd ed. San Diego, California: Academic Press.
48. Lockhart DJ, Kim PS. 1993. Electrostatic screening of charge and dipole interactions with the helix backbone. Science 260(5105):198-202.
49. Neal BL, Asthagiri D, Lenhoff AM. 1998. Molecular origins of osmotic second virial coefficients of proteins. Biophys J 75:2469-2477.
50. Taratuta VG HA, Thurston GM, Blankschtein D, Benedek GB. 1990. Liquid-liquid phase separation of aqueou lysozyme solutions: Effects of pH and salt identity. J Phys Chem 94:2140-2144.
51. Broide ML, Berland CR, Pande J, Ogun OO, Benedek GB. 1991. Binary-liquid phase separation of lens protein solutions. Proc Natl Acad Sci USA 88(13):5660-5664.